<DOC>
	<DOCNO>NCT02676778</DOCNO>
	<brief_summary>The purpose study evaluate objective response rate ( ORR ) E7777 participant relapse refractory peripheral T-cell lymphoma ( PTCL ) cutaneous T-cell lymphoma ( CTCL ) .</brief_summary>
	<brief_title>Study E7777 Patients With Relapsed Refractory Peripheral T-cell Lymphoma Cutaneous T-cell Lymphoma</brief_title>
	<detailed_description>This multicenter , single-arm , open label , Phase 2 evaluate efficacy , safety , pharmacokinetics immunogenicity E7777 participant relapse refractory PTCL CTCL .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<criteria>1 . Participants histological diagnosis peripheral Tcell lymphoma ( PTCL ) cutaneous Tcell lymphoma ( CTCL ) . 2 . Participant measurable disease . 3 . Participant previous systemic chemotherapy . 4 . Participant disease progression ( PD ) response ( complete response ( CR ) partial response ( PR ) ) systemic chemotherapy , relapse progressed systemic chemotherapy . 5 . Participant Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 1 . 6 . Participant adequate renal , liver bone marrow function . 7 . Male female participant â‰¥20 year age time informed consent . 8 . Participants provide write consent participate study . 1 . Participant serious complication history . 2 . Participant history hypersensitivity protein therapeutic . 3 . Participant positive Human immunodeficiency virus ( HIV ) antibody , Hepatitis C virus ( HCV ) antibody , Hepatitis B Surface ( HBs ) antigen . 4 . Participant malignancy activity PTCL CTCL within 36 month inform consent . 5 . Women childbearing potential man impregnate potential n't agree use medically effective method contraception . 6 . Woman pregnant lactating . 7 . Participant allogeneic stem cell transplantation . 8 . Participant decide inappropriate participate study investigator subinvestigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Peripheral T-cell lymphoma</keyword>
	<keyword>Cutaneous T-cell lymphoma</keyword>
	<keyword>E7777</keyword>
	<keyword>Phase 2</keyword>
</DOC>